Parking contd...
NEWS RELEASE
Oslo, October 1st. 2001
AFFITECH AND ISOGENICA AGREE EXCLUSIVE LICENCE TO NOVEL DISCOVERY TECHNOLOGY FOR HUMAN ANTIBODIES
Cambridge, UK / Oslo, Norway 1st October 2001---Isogenica Ltd, Cambridge, UK and Affitech AS, Oslo, Norway announced today that they have entered into a strategic collaboration and licensing agreement for the development and commercialisation of Isogenica’s proprietary Covalent Display Technology (CDT). For Affitech this provides a novel second generation platform for enhanced high throughput production of recombinant antibody products derived from their fully human libraries.
NEWS RELEASE
Oslo, September 3rd. 2001
Affitech collaborates with Norwegian National Institute of Public Health on discovery and pre-clinical validation of human antibodies
VZV first target for new human antibody programme within infectious diseases
September 3, 2001, Oslo, Norway - Affitech AS, the phage display antibody company today announced that it has signed a three-year collaborative agreement with the Norwegian National Institute of Public Health (NIPH). Under the collaboration, NIPH will provide specific viral targets for Affitech to utilise for the selection and development of human anti-viral antibodies from its proprietary antibody phage display libraries. Affitech will also generate new human antibody libraries from human donors with a specific immune history. Access to patient donors will enhance the development of human antibodies for prophylactic and therapeutic use, and Affitech intends to streamline this route to new antibody-based drugs.
NEWS RELEASE
Oslo, August 20th. 2001
Nycomed Amersham Extends Human Antibody Agreement with Affitech
Oslo, Norway, 20th August 2001 - Affitech AS announces the signing of a research agreement with Nycomed Amersham Imaging for the discovery of fully human antibodies. The agreement aims to develop new reagents for molecular imaging against targets provided by Nycomed Amersham. Affitech will retain rights to milestone and royalty payments from products emerging from the collaboration. The agreement is an extension of a previous agreement which commenced in 1999.
NEWS RELEASE
Oslo, April 2nd. 2001
Affitech AS further strengthens its patent positions within phage display of human antibody fragments
Oslo, Norway, 2nd April 2001 - Affitech AS has announced that it has been granted its first European patent on key technology related to phage display from the European Patent Office. The patent, [No. 547201], claims the use of phagemids as a vehicle for generating libraries of antibodies as fusions to coliphage protein pIII, and the subsequent display of these fusions proteins on phage particles. An equivalent patent, and divisionals thereof, have already been granted in the United States.
NEWS RELEASE
Oslo, Dec. 1st. 2000
Affitech AS acquires exclusive rights to novel vaccine delivery technology
Oslo, Norway, 1st December 2000 - Affitech AS, the recombinant human antibody company, today announced that it has secured an exclusive 9 months option to a novel vaccine delivery technology, called Troy-bodies, which has been developed by researchers at the University of Oslo and the Norwegian National Hospital. Upon execution, the option will be converted to an exclusive worldwide license with unrestricted sublicense rights.
NEWS RELEASE
Oslo, Sept. 5th. 2000
Affitech AS acquires Actigen Ltd.
Affitech AS (Oslo, Norway) has recently completed the acquisition of Actigen Ltd. from Active Biotech AB (Lund, Sweden). In addition to Actigen's distribution and license agreements, Affitech has also acquired a comprehensive package of intellectual property related to protein L and other affinity proteins and purification methods previously owned by Active Biotech AB, and its subsidiary, Actinova Limited (Cambridge, UK).
PRESS RELEASE
Oslo, Dec 10th, 1999
Affitech AS enters into research agreement with Amersham Pharmacia Biotech
Affitech AS and Amersham Pharmacia Biotech (APB) have signed a research agreement wherein Affitech will use its proprietary technology and libraries to isolate specific binders for APB. In the agreement, APB will provide the targets and Affitech will use its proprietary libraries to screen for high affinity binders to these targets. It is expected that this agreement will be extended to include a broader range of targets in the future. |
